Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PSTX

Poseida Therapeutics Inc

Apr 19 • 03:01PM ET

1.96

Dollar change -0.04
Percentage change -2.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO SCHA IWC GNOM DFAS AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.38	Insider Own	35.96%	Shs Outstand	95.64M	Perf Week	-28.21%
Market Cap	189.12M	Forward P/E	-	EPS next Y	-1.80	Insider Trans	0.00%	Shs Float	61.79M	Perf Month	-34.01%
Income	-123.43M	PEG	-	EPS next Q	-0.42	Inst Own	47.11%	Short Float	6.67%	Perf Quarter	-28.99%
Sales	64.70M	P/S	2.92	EPS this Y	-21.90%	Inst Trans	57.20%	Short Ratio	5.49	Perf Half Y	-15.88%
Book/sh	1.08	P/B	1.81	EPS next Y	-7.93%	ROA	-38.88%	Short Interest	4.12M	Perf Year	-26.87%
Cash/sh	2.20	P/C	0.89	EPS next 5Y	2.70%	ROE	-84.75%	52W Range	1.54 - 4.27	Perf YTD	-41.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.83%	ROI	-67.38%	52W High	-54.10%	Beta	0.53
Dividend TTM	-	Quick Ratio	3.18	Sales past 5Y	53.46%	Gross Margin	91.32%	52W Low	27.27%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	3.18	EPS Y/Y TTM	-27.66%	Oper. Margin	-200.15%	RSI (14)	28.26	Volatility	11.41% 8.32%
Employees	330	Debt/Eq	0.82	Sales Y/Y TTM	-50.42%	Profit Margin	-190.76%	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.77	EPS Q/Q	31.60%	Payout	-	Rel Volume	0.57	Prev Close	2.00
Sales Surprise	275.94%	EPS Surprise	30.05%	Sales Q/Q	148.68%	Earnings	Mar 07 AMC	Avg Volume	751.31K	Price	1.96
SMA20	-30.37%	SMA50	-39.21%	SMA200	-26.59%	Trades		Volume	365,452	Change	-2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-23	Initiated	H.C. Wainwright	Buy	$15
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight	$24
May-18-21	Initiated	BTIG Research	Buy	$40
Aug-04-20	Initiated	William Blair	Outperform
Aug-04-20	Initiated	Piper Sandler	Overweight	$30
Aug-04-20	Initiated	BofA Securities	Buy	$20

Apr-18-24 08:00AM	Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (PR Newswire)
Apr-17-24 09:00AM	Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus (PR Newswire)
Apr-08-24 12:00PM	Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma (PR Newswire)
Apr-01-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-25-24 04:05PM	Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer (PR Newswire)
04:05PM	Loading…
Mar-19-24 04:05PM	Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (PR Newswire)
Mar-13-24 04:05PM	Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma (PR Newswire) +7.57%
Mar-07-24 10:53PM	PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
10:45PM	Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
06:55PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 (PR Newswire)
Mar-04-24 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -10.77%
Jan-04-24 08:00AM	Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones (PR Newswire)
Dec-10-23 12:00PM	Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace) +5.58%
04:05PM	Loading…
Nov-09-23 04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 (PR Newswire)
Nov-07-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Nov-02-23 10:00AM	Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) +5.31%
09:01AM	Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-16-23 12:00PM	All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy (Zacks) +6.41%
Oct-09-23 04:30PM	Poseida Therapeutics Announces Leadership Transition (PR Newswire)
Oct-03-23 05:00PM	Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
Sep-05-23 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Aug-10-23 06:02AM	News Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Forecasts (Simply Wall St.)
Aug-08-23 05:40PM	Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023 (PR Newswire)
Aug-07-23 09:01AM	Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update (PR Newswire) +21.47%
09:00AM	Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy (PR Newswire)
Jul-31-23 08:23AM	The past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitable (Simply Wall St.)
Jul-05-23 08:00AM	Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies (PR Newswire)
08:00AM	Loading…
Jun-26-23 08:00AM	Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes (PR Newswire) -11.06%
Jun-01-23 08:00AM	Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders (PR Newswire)
May-23-23 08:00AM	Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day (PR Newswire)
May-22-23 08:00AM	Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis (PR Newswire) +9.30%
May-18-23 08:00AM	Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting (PR Newswire) -6.67%
May-11-23 06:11AM	Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -9.00%
May-10-23 12:00PM	What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock (Zacks)
May-09-23 07:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023 (PR Newswire)
May-02-23 04:30PM	Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting (PR Newswire)
May-01-23 08:00AM	Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference (PR Newswire)
Apr-17-23 06:48AM	Benign Growth For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Underpins Stock's 44% Plummet (Simply Wall St.)
Apr-13-23 08:00AM	Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors (PR Newswire)
Apr-11-23 04:05PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08:00AM	Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy (PR Newswire)
Apr-03-23 07:09AM	With 46% stake, Poseida Therapeutics, Inc. (NASDAQ:PSTX) seems to have captured institutional investors' interest (Simply Wall St.)
Mar-09-23 06:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.17%
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 (PR Newswire)
Mar-01-23 08:00AM	Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board (PR Newswire) -5.98%
Feb-22-23 08:00AM	Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PR Newswire)
Feb-21-23 06:50AM	Poseida Therapeutics (NASDAQ:PSTX) shareholders are still up 91% over 1 year despite pulling back 10.0% in the past week (Simply Wall St.)
Feb-15-23 08:50AM	Here's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength (Zacks) -8.05%
Feb-14-23 08:00AM	Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire)
Feb-08-23 08:00AM	Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 (PR Newswire)
Jan-31-23 04:05PM	Poseida Therapeutics Announces Board Change (PR Newswire)
Jan-27-23 08:50AM	Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-25-23 11:16AM	How to Nab a 78% Gain in 8 Weeks (InvestorPlace)
Jan-10-23 08:50AM	Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why (Zacks)
Jan-04-23 02:51PM	Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says (Benzinga) +14.51%
Dec-15-22 08:50AM	Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Dec-11-22 10:30AM	Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition (PR Newswire)
Dec-06-22 09:55AM	Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High? (Zacks) -5.29%
06:00AM	Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress (PR Newswire)
Nov-10-22 06:45PM	Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 (PR Newswire)
Nov-08-22 08:00AM	Poseida Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Nov-03-22 09:00AM	Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress (PR Newswire) +6.28%
09:00AM	Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition (PR Newswire)
Oct-25-22 06:11AM	Both individual investors who control a good portion of Poseida Therapeutics, Inc. (NASDAQ:PSTX) along with institutions must be dismayed after last week's 15% decrease (Simply Wall St.) +6.25%
Oct-05-22 08:09AM	Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting (PR Newswire) +6.29%
Sep-14-22 06:57AM	Investors in Poseida Therapeutics (NASDAQ:PSTX) have unfortunately lost 58% over the last year (Simply Wall St.)
Sep-07-22 04:05PM	Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) +10.62%
Aug-11-22 04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 (PR Newswire) +10.19%
Aug-08-22 04:05PM	Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -9.98%
Aug-04-22 08:00AM	Poseida Therapeutics Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:00AM	Poseida Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)
Aug-03-22 04:01PM	Poseida Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire) +85.60%
09:02AM	Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field (Benzinga)
07:30AM	Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies (PR Newswire)
Jul-26-22 08:00AM	Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board (PR Newswire)
Jun-29-22 04:05PM	Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products (PR Newswire)
Jun-02-22 08:00AM	Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders (PR Newswire)
May-18-22 08:00AM	Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors (PR Newswire) -10.31%
May-17-22 08:00AM	Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting (PR Newswire)
May-15-22 08:37AM	Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25 (Simply Wall St.)
May-12-22 06:05PM	Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 (PR Newswire)
May-09-22 08:22AM	What Percentage Of Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Do Insiders Own? (Simply Wall St.) -14.57%
May-02-22 04:30PM	Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (PR Newswire)
Apr-28-22 08:00AM	Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference (PR Newswire)
Mar-14-22 12:48PM	Investors in Poseida Therapeutics (NASDAQ:PSTX) from a year ago are still down 66%, even after 16% gain this past week (Simply Wall St.)
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 (PR Newswire)
Mar-01-22 07:47PM	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.30%
Feb-23-22 08:00AM	Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PR Newswire)
Feb-22-22 08:00AM	Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy (PR Newswire) -7.89%
Feb-17-22 08:00AM	Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium (PR Newswire) -15.20%
Feb-09-22 08:00AM	Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 (PR Newswire)
Jan-10-22 08:00AM	Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen (PR Newswire)
Jan-05-22 10:17AM	Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes (Zacks)

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTX

Poseida Therapeutics Inc

Upgrade your FINVIZ experience